# A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

> **NCT05714969** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 29 (actual)

## Conditions studied

- Thrombotic Thrombocytopenic Purpura (TTP)

## Interventions

- **BIOLOGICAL:** TAK-755

## Key facts

- **NCT ID:** NCT05714969
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-21
- **Primary completion:** 2026-04-16
- **Final completion:** 2026-04-16
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05714969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05714969, "A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05714969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*